SBFM Company Profile and Key Details

NASDAQ : SBFM

Sunshine Biopharma

$0.92

0.02020002+2.24%

Open: 1:54 PM

62.29

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Sunshine Biopharma, Inc. (SBFM) stock surged +2.24%, trading at $0.92 on NASDAQ, up from the previous close of $0.90. The stock opened at $0.86, fluctuating between $0.86 and $0.97 in the recent session.

Stock Snapshot

0.8998

Prev. Close

2.19M

Market Cap

0.86

Day Low

-0.15

P/E Ratio

-6.08

EPS (TTM)

-0.4

Cash Flow per Share

0.86

Open

2.38M

Number of Shares

0.97

Day High

99.96%

Free Float in %

0.89

Book Value

97.11K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 18, 2026	0.82	0.90	0.82	0.90	157.56K
Sep 17, 2026	1.01	1.01	0.84	0.84	337.19K
Sep 16, 2026	1.02	1.06	1.01	1.03	123.58K
Sep 15, 2026	1.07	1.07	1.02	1.03	85.98K
Sep 14, 2026	1.05	1.08	1.05	1.07	62.81K
Sep 11, 2026	1.10	1.11	1.05	1.06	97.76K
Sep 10, 2026	1.14	1.14	1.08	1.08	125.55K
Sep 09, 2026	1.14	1.15	1.11	1.12	87.05K
Sep 08, 2026	1.18	1.24	1.14	1.15	288.08K
Sep 04, 2026	1.14	1.14	1.11	1.14	81.27K
Sep 03, 2026	1.17	1.17	1.11	1.11	0
Sep 02, 2026	1.14	1.19	1.12	1.17	129.22K
Sep 01, 2026	1.12	1.15	1.11	1.13	102.41K
Aug 31, 2026	1.14	1.23	1.10	1.12	362.59K
Aug 28, 2026	1.28	1.28	1.14	1.15	443.77K
Aug 27, 2026	1.25	1.30	1.18	1.27	1.02M
Aug 26, 2026	1.30	1.31	1.01	1.24	9.34M
Aug 25, 2026	1.15	1.17	1.12	1.14	52.46K
Aug 24, 2026	1.17	1.17	1.12	1.16	83.81K
Aug 21, 2026	1.15	1.17	1.14	1.16	98.74K

Contact Details

Fort Lauderdale, FL 33301

United States

https://www.sunshinebiopharma.com 514 426 6161

About Company

Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.

Stock Peers

ITCI

Intra-Cellular Therapies, Inc.$131.87 LNTH

-0.25-0.25%

Lantheus Holdings, Inc.$100.55 ANIP

0.75+0.99%

ANI Pharmaceuticals, Inc.$76.14 ETON

-1.57-2.75%

Eton Pharmaceuticals, Inc.$55.50 ALKS

-3.32-7.11%

Alkermes plc$43.39 SUPN

-0.92-2.14%

Supernus Pharmaceuticals, Inc.$42.00 INDV

-0.81-2.27%

Indivior Pharmaceuticals Inc$34.88 PAHC

0.115+0.33%

Phibro Animal Health Corporation$34.56 HROW

-0.05-0.15%

Harrow Health, Inc.$33.08 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98

Company Overview

Sunshine Biopharma, Inc. (NASDAQ:SBFM) closed at $0.92 USD, gaining $0.02 (2.24%) from the previous close of $0.90. The stock is currently mid-range between its 52-week high and low $0.82 and $24.30. With a market capitalization of about $2.19 million, Sunshine Biopharma, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.32). Key stats such as the average daily volume over the past year has been around 524.50 thousand shares, volume is running light vs its 52-week average. Headquartered in Fort Lauderdale, FL, Sunshine Biopharma, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Steve N. Slilaty, the company employs approximately 50 people and listed since February 15, 2022. Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 3.27%, SMA50 -1.83%, SMA200 -16.03%). The stock’s 14-day RSI is 53.25 (neutral), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -68.46% below its high and over 8.85% above its low. Average 10-day trading volume of 144.15 thousand shares is below the 3-month average of 514.14 thousand, indicating normal recent market interest.

Valuation Metrics

Sunshine Biopharma, Inc. trades at a P/E ratio of -0.09, slightly below the S&P 500 average, with a price-to-sales ratio of 0.06 and a price-to-book ratio of 0.04 suggesting the stock is closer to book value. The P/FCF stands at -0.47, also above market averages.

Dividend & Fair Value

Sunshine Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.08. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Sunshine Biopharma, Inc. generated EPS of -$1.86 over the past year. Five-year average earnings growth is 82.07%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $7.00. The high target offers 677.78% upside. The low target suggests 677.78% downside. The mean target is $7.00. This offers 677.78% upside. Sunshine Biopharma, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 13, 2026, missed forecasts by -4.17%. The prior quarter beat by 56.25%. Over the last six quarters, Apple has recorded several small beats. These include 254.55% in August 12, 2025.

Shareholding & Insider Activity

Sunshine Biopharma, Inc. has 4.56 million shares outstanding. The public float is 4.55 million shares, elevated short interest at 6.33% of float. This equals 288.27 thousand shares. The short ratio is 4.7 days. Institutional investors hold 7.26% of the float. Insiders own 1.77%.

Financial & Profitability Overview

Over the trailing twelve months, Sunshine Biopharma generated $24.09M in revenue, or $0.99 per share. Gross margin was 33.99%, operating margin -19.86%, and net profit margin -18.70%. Returns are negative, with ROA at -16.48% and ROE at -21.25%.
On valuation metrics, Sunshine Biopharma trades at a P/E of -0.09, P/S of 0.06 and P/B of 0.04. The current ratio is 5.46 and quick ratio is 3.30. Operationally, the company’s inventory turnover is 2.05 and cash conversion cycle is 148.60 days. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -7.86.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Sunshine Biopharma posted revenue of $24.09M, down slightly from $4.35M in the prior quarter. Gross profit was $8.19M (margin 33.99%). Operating income was - $4.79M (margin -19.9%). Net income was- $4.51M (EPS - $0.19).
The company ended the quarter with $16.29M in cash and short-term investments, a total debt of $657.71K, and net debt of - $15.63M. Total assets were $27.35M, with equity of $21.21M. Financials further reflected weakness, with operating cash flow of - $8.78M, free cash flow of - $9.56M, and capital expenditures of - $788.10K.

Price Forecast & Outlook

Our AI price prediction model suggests that Sunshine Biopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.31%, with price expected at $0.78 by October 02, 2026, within a range of $0.72 to $0.84 3-Month Outlook: Projected fall of -88.89%, reaching $0.10 by December 17, 2026, with a range of $0.00 to $0.45. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 17, 2027, within a range of $0.00 to $54.90.

Key Takeaways

Sunshine Biopharma, Inc. (NASDAQ:SBFM) shares are flat -1.63% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Sunshine Biopharma, Inc. trading at a premium to the broader market with a P/E of -0.09. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.20, suggesting 811.31% upside. Our AI forecast model points to short-term weakness (-13.31% over two weeks), a medium-term fall (-88.89% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Sunshine Biopharma, Inc. (SBFM) stock price?

Sunshine Biopharma, Inc. (NASDAQ: SBFM) stock price is $0.92 in the last trading session. During the trading session, SBFM stock reached the peak price of $0.97 while $0.86 was the lowest point it dropped to. The percentage change in SBFM stock occurred in the recent session was 2.24% while the dollar amount for the price change in SBFM stock was $0.02.

SBFM's industry and sector of operation?

The NASDAQ listed SBFM is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Sunshine Biopharma, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SBFM?

No Data

How SBFM did perform over past 52-week?

SBFM's closing price is 9.73% higher than its 52-week low of $0.82 where as its distance from 52-week high of $24.30 is -96.3%.

How many employees does SBFM have?

Number of SBFM employees currently stands at 50.

Link for SBFM official website?

Official Website of SBFM is: https://www.sunshinebiopharma.com

How do I contact SBFM?

SBFM could be contacted at phone 514 426 6161 and can also be accessed through its website. SBFM operates from 333 Las Olas Way, Fort Lauderdale, FL 33301, United States.

How many shares of SBFM are traded daily?

SBFM stock volume for the day was 97.11K shares. The average number of SBFM shares traded daily for last 3 months was 524.5K.

What is the market cap of SBFM currently?

The market value of SBFM currently stands at $2.19M with its latest stock price at $0.92 and 2.38M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	50
Beta	1.32
Sales or Revenue	$24.09M
5Y Sales Change%	66.466%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

SBFM Company Profile and Key Details

Sunshine Biopharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Price Forecast & Outlook

Key Takeaways